Business · Companies · 1 day ago
StemRIM may record 900 million yen in revenue in fiscal 2027
StemRIM is a drug developer that grew out of Osaka University in Japan.
It is working on medicines designed to encourage the body to repair damaged tissue, including a drug called redasemtide.
Shionogi is developing redasemtide for two medical uses and has reported clinical trial results.
StemRIM had no revenue for three years and posted an operating loss of about 2 billion yen in the year to July 2026.
It did not issue a revenue forecast for the year to July 2027, saying it was difficult to estimate its results.
An estimate puts its revenue for that year at 900 million yen, potentially from development milestones, and its operating loss at about 1.1 billion yen.
Preliminary results for a trial in acute stroke were described as disappointing, so the expected revenue remains uncertain.
Toyo Keizai forecasts that StemRim may record ¥900 million in sales for the fiscal year ending July 2027.
The estimate follows three consecutive fiscal years with no sales.
Toyo Keizai expects StemRim’s operating loss to narrow to ¥1.1 billion, from about ¥2 billion in the previous fiscal year.
StemRim did not disclose its earnings forecast, saying it was difficult to calculate.
The company also announced clinical trial results for its drug candidate redasemtide, developed by Shionogi for two indications.
- Who
- StemRim, a drug-development venture launched from Osaka University.
- What
- Toyo Keizai forecasts ¥900 million in sales for StemRim in fiscal 2027, potentially including development milestone revenue.
- When
- The fiscal year ends in July 2027. StemRim announced its previous fiscal-year results on September 9.
- Where
- Japan; the article identifies StemRim as an Osaka University venture.
- Why
- Toyo Keizai’s forecast is based on company explanations, including information from a September 11 earnings briefing. The reason for the potential milestone revenue is not stated.
This story does not have two clearly opposing sides.
Results of 100% or more were obtained
StemRim announced its results for the fiscal year ending July 2026, reporting no sales and an operating loss of about ¥2 billion.
StemRim held an earnings briefing, which Toyo Keizai said it used in making its forecasts.
Toyo Keizai published its forecast for StemRim’s fiscal 2027 and fiscal 2028 results.
- Fiscal 2027 sales forecast
- ¥900 million
- Fiscal 2027 operating loss forecast
- ¥1.1 billion
- Fiscal 2026 sales
- Zero
- Fiscal 2026 operating loss
- About ¥2 billion
- Drug candidate
- Redasemtide
- Development partner
- Shionogi
Sources
Related news
Employee moves from Shibuya to a 50-year-old resort condo in Zushi
Japan cruise companies target younger travellers with shorter, cheaper trips
Japanese brewer creates wobbly glass to encourage drinking water with beer
Japan orders Prudential Life to suspend sales of new policies
Japanese companies in China fall to lowest level in 16 years
Japan’s economy grew 1.4% in April-June, but domestic demand remained weak
Japan becomes India’s top source of FDI in first quarter of FY27
JR East to launch teppay digital payments on Oct. 20
Physical AI could create opportunities for Japanese companies
Kawasaki Heavy targets 1 trillion yen in defense sales by mid-2030s
Sumitomo Bakelite to expand chip packaging materials output in China and Singapore
